by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION Greater white matter hyperintensities (WMHs) on magnetic resonance imaging (MRI) are seen with transactive response DNA-binding protein 43 (TDP-43) pathology in frontotemporal lobar degeneration (FTLD-TDP). WMH associations with TDP-43 pathology...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION Medicare’s Annual Wellness Visit (AWV) is a logical opportunity for early detection of cognitive impairment, but recent data for uptake and cognitive assessments during it are lacking. METHODS We surveyed Medicare beneficiaries of a...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is the most common neurodegenerative disease, characterized by damage to cortical circuits. However, the mechanisms underlying AD-associated changes in long-range circuits remain poorly understood. METHODS In this...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract INTRODUCTION Novel fluid biomarkers for tracking neurodegeneration specific to Alzheimer’s disease (AD) are greatly needed. METHODS Using two independent well-characterized cohorts (n = 881 in total), we investigated the group differences in plasma...
by Clinical Neuropsychologist | Friday, January 17, 2025 | Dementia
Abstract Extracellular vesicles (EVs) have emerged as novel blood-based biomarkers for various pathologies. The development of methods to enrich cell-specific EVs from biofluids has enabled us to monitor difficult-to-access organs, such as the brain, in real time...
